The Experts below are selected from a list of 228 Experts worldwide ranked by ideXlab platform

Michael M Johns - One of the best experts on this subject based on the ideXlab platform.

  • vocal outcome measures after bilateral Posterior Cricoarytenoid Muscle botulinum toxin injections for abductor spasmodic dysphonia
    Otolaryngology-Head and Neck Surgery, 2008
    Co-Authors: Adam M Klein, Benjamin C Stong, Justin C Wise, John M Delgaudio, Edie R Hapner, Michael M Johns
    Abstract:

    Objective To review vocal outcome measures, using the Voice Related Quality of Life (VRQOL) index, after simultaneous bilateral Posterior Cricoarytenoid Muscle botulinum toxin injections. Study Design Case series. Setting Tertiary care academic clinic. Subjects and Methods Fourteen subjects with abductor spasmodic dysphonia received 37 simultaneous bilateral Posterior Cricoarytenoid Muscle botulinum toxin injections for isolated abductor spasmodic dysphonia (ABSD) over a 16-month period. Main Outcome Measures VRQOL index. Results Of the 37 injections, 33 of 37 (89%) resulted in improvement. Three injections resulted in no improvement, and one injection resulted in a worse VRQOL. The overall VRQOL mean improvement was 19.8 (range 5-53), with an average pre/postinjection VRQOL interval of 36 days (range 21-45 days). Conclusions Simultaneous bilateral Posterior Cricoarytenoid Muscle botulinum injections result in a statistically significant improvement in VRQOL index scores for a high percentage of ABSD patients, thus improving patient quality of life.

  • Safety of simultaneous bilateral botulinum toxin injections for abductor spasmodic dysphonia
    Archives of otolaryngology--head & neck surgery, 2005
    Co-Authors: Benjamin C Stong, John M Delgaudio, Edie R Hapner, Michael M Johns
    Abstract:

    Objective To review the safety of simultaneous bilateral Posterior Cricoarytenoid Muscle botulinum toxin injections. Design Retrospective case series review. Setting Tertiary care academic clinic. Patients Twenty-one patients with abductor spasmodic dysphonia. Interventions Patients received 100 simultaneous bilateral Posterior Cricoarytenoid Muscle botulinum toxin injections for isolated abductor spasmodic dysphonia over a 6-year period. Main Outcome Measures Major and minor complications, injection dosing, and demographics. Results The total bilateral botulinum toxin injection dose per session ranged from 2.50 to 7.50 U, and the average total bilateral dose per patient was 4.70 U. There were no major complications, and minor complications were self-limited. There was a 5% incidence of significant dyspnea and a 2% incidence of dysphagia, and all patients were treated conservatively. The average doses at which dyspnea and dysphagia occurred were 4.97 and 5.56 U, respectively. Conclusions This case series demonstrates that simultaneous bilateral Posterior Cricoarytenoid Muscle botulinum toxin injection is safe up to the highest doses reported. Complications with this approach are consistent with those previously reported using other methods. Prospective studies on vocal outcome measures are needed for simultaneous bilateral Posterior Cricoarytenoid Muscle botulinum toxin injections to evaluate the efficacy of this technique.

Benjamin C Stong - One of the best experts on this subject based on the ideXlab platform.

  • ORIGINAL ARTICLE Safety of Simultaneous Bilateral Botulinum Toxin Injections for Abductor Spasmodic Dysphonia
    2014
    Co-Authors: Benjamin C Stong, Md John, M. Delgaudio, Md Edie, R. Hapner, Phd Michael M. Johns
    Abstract:

    Objective: To review the safety of simultaneous bilat-eral Posterior Cricoarytenoid Muscle botulinum toxin injections. Design: Retrospective case series review. Setting: Tertiary care academic clinic. Patients: Twenty-one patients with abductor spas-modic dysphonia. Interventions: Patients received 100 simultaneous bi-lateral Posterior Cricoarytenoid Muscle botulinum toxin injections for isolated abductor spasmodic dysphonia over a 6-year period. Main Outcome Measures: Major and minor compli-cations, injection dosing, and demographics. Results:The total bilateral botulinum toxin injection dose per session ranged from 2.50 to 7.50 U, and the average total bilateral dose per patient was 4.70 U. There were no major complications, and minor complications were self-limited. There was a 5 % incidence of significant dys-pnea and a 2 % incidence of dysphagia, and all patients were treated conservatively. The average doses at which dyspnea and dysphagia occurred were 4.97 and 5.56 U, respectively. Conclusions: This case series demonstrates that simul-taneous bilateral Posterior Cricoarytenoid Muscle botu-linum toxin injection is safe up to the highest doses reported. Complications with this approach are consis-tent with those previously reported using other meth-ods. Prospective studies on vocal outcome measures are needed for simultaneous bilateral Posterior cricoaryte-noid Muscle botulinum toxin injections to evaluate the efficacy of this technique

  • vocal outcome measures after bilateral Posterior Cricoarytenoid Muscle botulinum toxin injections for abductor spasmodic dysphonia
    Otolaryngology-Head and Neck Surgery, 2008
    Co-Authors: Adam M Klein, Benjamin C Stong, Justin C Wise, John M Delgaudio, Edie R Hapner, Michael M Johns
    Abstract:

    Objective To review vocal outcome measures, using the Voice Related Quality of Life (VRQOL) index, after simultaneous bilateral Posterior Cricoarytenoid Muscle botulinum toxin injections. Study Design Case series. Setting Tertiary care academic clinic. Subjects and Methods Fourteen subjects with abductor spasmodic dysphonia received 37 simultaneous bilateral Posterior Cricoarytenoid Muscle botulinum toxin injections for isolated abductor spasmodic dysphonia (ABSD) over a 16-month period. Main Outcome Measures VRQOL index. Results Of the 37 injections, 33 of 37 (89%) resulted in improvement. Three injections resulted in no improvement, and one injection resulted in a worse VRQOL. The overall VRQOL mean improvement was 19.8 (range 5-53), with an average pre/postinjection VRQOL interval of 36 days (range 21-45 days). Conclusions Simultaneous bilateral Posterior Cricoarytenoid Muscle botulinum injections result in a statistically significant improvement in VRQOL index scores for a high percentage of ABSD patients, thus improving patient quality of life.

  • Safety of simultaneous bilateral botulinum toxin injections for abductor spasmodic dysphonia
    Archives of otolaryngology--head & neck surgery, 2005
    Co-Authors: Benjamin C Stong, John M Delgaudio, Edie R Hapner, Michael M Johns
    Abstract:

    Objective To review the safety of simultaneous bilateral Posterior Cricoarytenoid Muscle botulinum toxin injections. Design Retrospective case series review. Setting Tertiary care academic clinic. Patients Twenty-one patients with abductor spasmodic dysphonia. Interventions Patients received 100 simultaneous bilateral Posterior Cricoarytenoid Muscle botulinum toxin injections for isolated abductor spasmodic dysphonia over a 6-year period. Main Outcome Measures Major and minor complications, injection dosing, and demographics. Results The total bilateral botulinum toxin injection dose per session ranged from 2.50 to 7.50 U, and the average total bilateral dose per patient was 4.70 U. There were no major complications, and minor complications were self-limited. There was a 5% incidence of significant dyspnea and a 2% incidence of dysphagia, and all patients were treated conservatively. The average doses at which dyspnea and dysphagia occurred were 4.97 and 5.56 U, respectively. Conclusions This case series demonstrates that simultaneous bilateral Posterior Cricoarytenoid Muscle botulinum toxin injection is safe up to the highest doses reported. Complications with this approach are consistent with those previously reported using other methods. Prospective studies on vocal outcome measures are needed for simultaneous bilateral Posterior Cricoarytenoid Muscle botulinum toxin injections to evaluate the efficacy of this technique.

John M Delgaudio - One of the best experts on this subject based on the ideXlab platform.

  • vocal outcome measures after bilateral Posterior Cricoarytenoid Muscle botulinum toxin injections for abductor spasmodic dysphonia
    Otolaryngology-Head and Neck Surgery, 2008
    Co-Authors: Adam M Klein, Benjamin C Stong, Justin C Wise, John M Delgaudio, Edie R Hapner, Michael M Johns
    Abstract:

    Objective To review vocal outcome measures, using the Voice Related Quality of Life (VRQOL) index, after simultaneous bilateral Posterior Cricoarytenoid Muscle botulinum toxin injections. Study Design Case series. Setting Tertiary care academic clinic. Subjects and Methods Fourteen subjects with abductor spasmodic dysphonia received 37 simultaneous bilateral Posterior Cricoarytenoid Muscle botulinum toxin injections for isolated abductor spasmodic dysphonia (ABSD) over a 16-month period. Main Outcome Measures VRQOL index. Results Of the 37 injections, 33 of 37 (89%) resulted in improvement. Three injections resulted in no improvement, and one injection resulted in a worse VRQOL. The overall VRQOL mean improvement was 19.8 (range 5-53), with an average pre/postinjection VRQOL interval of 36 days (range 21-45 days). Conclusions Simultaneous bilateral Posterior Cricoarytenoid Muscle botulinum injections result in a statistically significant improvement in VRQOL index scores for a high percentage of ABSD patients, thus improving patient quality of life.

  • Safety of simultaneous bilateral botulinum toxin injections for abductor spasmodic dysphonia
    Archives of otolaryngology--head & neck surgery, 2005
    Co-Authors: Benjamin C Stong, John M Delgaudio, Edie R Hapner, Michael M Johns
    Abstract:

    Objective To review the safety of simultaneous bilateral Posterior Cricoarytenoid Muscle botulinum toxin injections. Design Retrospective case series review. Setting Tertiary care academic clinic. Patients Twenty-one patients with abductor spasmodic dysphonia. Interventions Patients received 100 simultaneous bilateral Posterior Cricoarytenoid Muscle botulinum toxin injections for isolated abductor spasmodic dysphonia over a 6-year period. Main Outcome Measures Major and minor complications, injection dosing, and demographics. Results The total bilateral botulinum toxin injection dose per session ranged from 2.50 to 7.50 U, and the average total bilateral dose per patient was 4.70 U. There were no major complications, and minor complications were self-limited. There was a 5% incidence of significant dyspnea and a 2% incidence of dysphagia, and all patients were treated conservatively. The average doses at which dyspnea and dysphagia occurred were 4.97 and 5.56 U, respectively. Conclusions This case series demonstrates that simultaneous bilateral Posterior Cricoarytenoid Muscle botulinum toxin injection is safe up to the highest doses reported. Complications with this approach are consistent with those previously reported using other methods. Prospective studies on vocal outcome measures are needed for simultaneous bilateral Posterior Cricoarytenoid Muscle botulinum toxin injections to evaluate the efficacy of this technique.

Edie R Hapner - One of the best experts on this subject based on the ideXlab platform.

  • vocal outcome measures after bilateral Posterior Cricoarytenoid Muscle botulinum toxin injections for abductor spasmodic dysphonia
    Otolaryngology-Head and Neck Surgery, 2008
    Co-Authors: Adam M Klein, Benjamin C Stong, Justin C Wise, John M Delgaudio, Edie R Hapner, Michael M Johns
    Abstract:

    Objective To review vocal outcome measures, using the Voice Related Quality of Life (VRQOL) index, after simultaneous bilateral Posterior Cricoarytenoid Muscle botulinum toxin injections. Study Design Case series. Setting Tertiary care academic clinic. Subjects and Methods Fourteen subjects with abductor spasmodic dysphonia received 37 simultaneous bilateral Posterior Cricoarytenoid Muscle botulinum toxin injections for isolated abductor spasmodic dysphonia (ABSD) over a 16-month period. Main Outcome Measures VRQOL index. Results Of the 37 injections, 33 of 37 (89%) resulted in improvement. Three injections resulted in no improvement, and one injection resulted in a worse VRQOL. The overall VRQOL mean improvement was 19.8 (range 5-53), with an average pre/postinjection VRQOL interval of 36 days (range 21-45 days). Conclusions Simultaneous bilateral Posterior Cricoarytenoid Muscle botulinum injections result in a statistically significant improvement in VRQOL index scores for a high percentage of ABSD patients, thus improving patient quality of life.

  • Safety of simultaneous bilateral botulinum toxin injections for abductor spasmodic dysphonia
    Archives of otolaryngology--head & neck surgery, 2005
    Co-Authors: Benjamin C Stong, John M Delgaudio, Edie R Hapner, Michael M Johns
    Abstract:

    Objective To review the safety of simultaneous bilateral Posterior Cricoarytenoid Muscle botulinum toxin injections. Design Retrospective case series review. Setting Tertiary care academic clinic. Patients Twenty-one patients with abductor spasmodic dysphonia. Interventions Patients received 100 simultaneous bilateral Posterior Cricoarytenoid Muscle botulinum toxin injections for isolated abductor spasmodic dysphonia over a 6-year period. Main Outcome Measures Major and minor complications, injection dosing, and demographics. Results The total bilateral botulinum toxin injection dose per session ranged from 2.50 to 7.50 U, and the average total bilateral dose per patient was 4.70 U. There were no major complications, and minor complications were self-limited. There was a 5% incidence of significant dyspnea and a 2% incidence of dysphagia, and all patients were treated conservatively. The average doses at which dyspnea and dysphagia occurred were 4.97 and 5.56 U, respectively. Conclusions This case series demonstrates that simultaneous bilateral Posterior Cricoarytenoid Muscle botulinum toxin injection is safe up to the highest doses reported. Complications with this approach are consistent with those previously reported using other methods. Prospective studies on vocal outcome measures are needed for simultaneous bilateral Posterior Cricoarytenoid Muscle botulinum toxin injections to evaluate the efficacy of this technique.

Per Mattsson - One of the best experts on this subject based on the ideXlab platform.

  • collateral reinnervation by the superior laryngeal nerve after recurrent laryngeal nerve injury
    Muscle & Nerve, 2008
    Co-Authors: Jonas Hydman, Per Mattsson
    Abstract:

    This study investigates the role of the intact superior laryngeal nerve (SLN) in the reinnervation process of one of the laryngeal Muscles, the Posterior Cricoarytenoid Muscle (PCA), following recurrent laryngeal nerve (RLN) injury. Using a chronic RLN injury model in the adult rat, PCA reinnervation was assessed by retrograde double-tracing techniques in combination with electrophysiology and immunohistochemistry of Muscle sections. The results demonstrate that the PCA receives dual innervation from both laryngeal nerves even in the uninjured system. Functionally significant collateral reinnervation originates from intact SLN fibers following RLN injury, mainly due to intramuscular sprouting rather than by recruitment of more motor neurons. This may be important when choosing surgical and/or medical treatment for patients with RLN injury.